| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Endogenous metabolite; uridine phosphorylase; uridine kinase; RNA polymerase; pyrimidine nucleoside transporters. Uridine is phosphorylated to UMP by uridine kinase and converted to UDP and UTP for RNA synthesis. It also serves as a substrate for uridine phosphorylase, yielding uracil and ribose-1-phosphate for salvage pathways.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, Uridine 13C-3 is used for pulse-labeling of nascent RNA in cultured cells. It is incorporated into RNA within 15-30 minutes of addition to culture medium. The compound enables quantification of RNA synthesis rates and half-life by tracking 13C enrichment in extracted RNA. It also supports nucleotide salvage pathway studies. |
| ln Vivo |
In vivo, Uridine 13C-3 is used for metabolic tracing of RNA turnover in animal tissues. Following administration, the 13C label is incorporated into tissue RNA, enabling quantification of RNA synthesis and degradation rates in liver, brain, and other organs. It also supports studies of nucleoside transport and pyrimidine metabolism in vivo.
|
| Enzyme Assay |
For RNA synthesis assays, cells are pulsed with Uridine 13C-3 (100-500 μM) for 15-60 minutes. RNA is extracted using TRIzol or column-based methods. 13C enrichment in RNA is quantified by LC-MS/MS after enzymatic digestion to nucleosides. RNA half-life is determined by chase experiments with excess unlabeled uridine.
|
| Cell Assay |
For pulse-chase labeling, cells are cultured in medium containing Uridine 13C-3 (100-500 μM) for 15-60 minutes (pulse), then washed and cultured in medium with excess unlabeled uridine (3 mM) for 0-8 hours (chase). RNA is extracted at each time point, and 13C enrichment is quantified by LC-MS/MS to determine RNA half-life.
|
| Animal Protocol |
For in vivo RNA turnover studies, mice receive Uridine 13C-3 (50-200 mg/kg) via intraperitoneal injection or oral gavage. Tissues (liver, brain) are collected at defined time points (0-24 hours). RNA is extracted, digested to nucleosides, and analyzed by LC-MS/MS to quantify 13C enrichment. For kinetic studies, multiple doses or continuous infusion may be used.
|
| References |
| Molecular Formula |
C14H13N4CL
|
|---|---|
| Molecular Weight |
272.73282
|
| Exact Mass |
245.073
|
| CAS # |
478511-16-9
|
| Related CAS # |
Uridine;58-96-8;Uridine-13C;201996-62-5;Uridine-13C5;159496-16-9;Uridine-13C,15N2;369656-75-7;Uridine-15N2;92487-68-8;Uridine-13C-1;478511-11-4;Uridine-13C-2;478511-14-7;Uridine-d2;82740-98-5;Uridine-d;89434-96-8;Uridine 13C-4;35803-42-0;Uridine-d2-1;40632-21-1
|
| PubChem CID |
123262984
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.36 g/cm3
|
| Boiling Point |
514.6ºC at 760 mmHg
|
| Flash Point |
265ºC
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
ClC1=CC2C(C3=CC=CN3)=NCC(NC)=NC=2C=C1
|
| InChi Key |
DRTQHJPVMGBUCF-GYMNKEIPSA-N
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1/i3+1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxy(113C)methyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6666 mL | 18.3332 mL | 36.6663 mL | |
| 5 mM | 0.7333 mL | 3.6666 mL | 7.3333 mL | |
| 10 mM | 0.3667 mL | 1.8333 mL | 3.6666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
